MetaADEDB 2.0 @ LMMD
oritavancin
(PWTROOMOPLCZHB-BHYQHFGMSA-N)
Structure
SMILES
OP(=O)(O)O.OP(=O)(O)O.OC[C@H]1O[C@@H](Oc2c3Oc4ccc(cc4Cl)[C@@H](O)[C@@H](NC(=O)[C@@H](CC(C)C)NC)C(=O)N[C@H](C(=O)N[C@@H]4c(c3)cc2Oc2ccc(cc2Cl)[C@@H](O[C@@H]2O[C@@H](C)[C@@H]([C@@](C2)(C)N)O)[C@@H]2NC(=O)[C@H](NC4=O)c3ccc(c(c3)c3c(O)cc(cc3[C@H](NC2=O)C(=O)O)O)O)CC(=O)N)[C@@H]([C@H]([C@@H]1O)O)O[C@@H]1O[C@@H](C)[C@@H]([C@@](C1)(C)NCc1ccc(cc1)c1ccc(cc1)Cl)O
Molecular Formula:
C86H103Cl3N10O34P2
Molecular Weight:
1989.090
Log P:
6.8553
Hydrogen Bond Acceptor:
44
Hydrogen Bond Donor:
26
TPSA:
736.12
CAS Number(s):
192564-14-0
Synonym(s)
1.
oritavancin
2.
LY 333328
3.
LY-333328
4.
LY333328
5.
Orbactiv
External Link(s)
MeSHC100708
PubChem Compound53297457
ChEBI83305
CHEMBLCHEMBL3989766
KEGGdr:D05271
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1PruritusFAERS: 76US FAERS
2UrticariaFAERS: 53US FAERS
3NauseaFAERS: 27US FAERS
4No adverse eventFAERS: 27US FAERS
5ChillsFAERS: 26US FAERS
6Back PainFAERS: 25US FAERS
7ErythemaFAERS: 23US FAERS
8Drug ineffectiveFAERS: 21US FAERS
9Chest PainFAERS: 19US FAERS
10Red man syndromeFAERS: 18US FAERS
11VomitingFAERS: 18US FAERS
12Chest discomfortFAERS: 15US FAERS
13HypersensitivityFAERS: 15US FAERS
14HeadacheFAERS: 11US FAERS
15Infusion Site ExtravasationFAERS: 11US FAERS
16FlushingFAERS: 10US FAERS
17TachycardiaFAERS: 8US FAERS
18DizzinessFAERS: 7US FAERS
19PainFAERS: 7US FAERS
20AnxietyFAERS: 5US FAERS
21Blood glucose increasedFAERS: 5US FAERS
22Feeling ColdFAERS: 5US FAERS
23InfectionFAERS: 5US FAERS
24TremorFAERS: 5US FAERS
25Burning sensationFAERS: 4US FAERS
26CellulitisFAERS: 4US FAERS
27ExtravasationFAERS: 4US FAERS
28Neck PainFAERS: 4US FAERS
29Skin reactionFAERS: 4US FAERS
30Abdominal PainFAERS: 3US FAERS
31ArthralgiaFAERS: 3US FAERS
32Incorrect drug administration rateFAERS: 3US FAERS
33Infusion site painFAERS: 3US FAERS
34Musculoskeletal PainFAERS: 3US FAERS
35MyalgiaFAERS: 3US FAERS
36Peripheral swellingFAERS: 3US FAERS
37Respiratory DepressionFAERS: 3US FAERS
38SwellingFAERS: 3US FAERS
39treatment failureFAERS: 3US FAERS
40Acute myocardial infarctionFAERS: 2US FAERS
41AstheniaFAERS: 2US FAERS
42Cardiac ArrestFAERS: 2US FAERS
43Drug effect incompleteFAERS: 2US FAERS
44Drug ineffective for unapproved indicationFAERS: 2US FAERS
45Injection site thrombosisFAERS: 2US FAERS
46Lip swellingFAERS: 2US FAERS
47MalaiseFAERS: 2US FAERS
48PalpitationsFAERS: 2US FAERS
49Rash erythematousFAERS: 2US FAERS
50RestlessnessFAERS: 2US FAERS
51Throat irritationFAERS: 2US FAERS
52ThrombophlebitisFAERS: 2US FAERS
53Wrong technique in product usage processFAERS: 2US FAERS
54Accidental exposure to productFAERS: 1US FAERS
55AgitationFAERS: 1US FAERS
56Anaphylactic shockFAERS: 1US FAERS
57AngioedemaFAERS: 1US FAERS
58BlepharospasmFAERS: 1US FAERS
59Blood glucose decreasedFAERS: 1US FAERS
60Bone painFAERS: 1US FAERS
61CyanosisFAERS: 1US FAERS
62Deep Vein ThrombosisFAERS: 1US FAERS
63DehydrationFAERS: 1US FAERS
64DiscomfortFAERS: 1US FAERS
65Disease ProgressionFAERS: 1US FAERS
66Drug administration errorFAERS: 1US FAERS
67Feeling abnormalFAERS: 1US FAERS
68Flank PainFAERS: 1US FAERS
69Fluid overloadFAERS: 1US FAERS
70Head discomfortFAERS: 1US FAERS
71HyperpyrexiaFAERS: 1US FAERS
72HypotensionFAERS: 1US FAERS
73HypoxiaFAERS: 1US FAERS
74Incorrect route of product administrationFAERS: 1US FAERS
75Infusion site dischargeFAERS: 1US FAERS
76Infusion site inflammationFAERS: 1US FAERS
77Infusion site phlebitisFAERS: 1US FAERS
78Infusion site pruritusFAERS: 1US FAERS
79Infusion site reactionFAERS: 1US FAERS
80Infusion site streakingFAERS: 1US FAERS
81Infusion site swellingFAERS: 1US FAERS
82Infusion site urticariaFAERS: 1US FAERS
83Injection Site ReactionFAERS: 1US FAERS
84Injection site urticariaFAERS: 1US FAERS
85LeukopeniaFAERS: 1US FAERS
86Mechanical urticariaFAERS: 1US FAERS
87Medication ErrorFAERS: 1US FAERS
88Muscle tightnessFAERS: 1US FAERS
89Myocardial InfarctionFAERS: 1US FAERS
90NecrosisFAERS: 1US FAERS
91OsteomyelitisFAERS: 1US FAERS
92PallorFAERS: 1US FAERS
93Periorbital abscessFAERS: 1US FAERS
94PhlebitisFAERS: 1US FAERS
95Product container issueFAERS: 1US FAERS
96Product reconstitution quality issueFAERS: 1US FAERS
97Pulmonary EmbolismFAERS: 1US FAERS
98SoporFAERS: 1US FAERS
99Subcutaneous AbscessFAERS: 1US FAERS
100ThrombocytopeniaFAERS: 1US FAERS
101ThrombosisFAERS: 1US FAERS
102Unevaluable eventFAERS: 1US FAERS
103Unresponsive to stimuliFAERS: 1US FAERS
104Vascular access site ruptureFAERS: 1US FAERS
105VasculitisFAERS: 1US FAERS
106Wrong drug administeredFAERS: 1US FAERS
107furuncleFAERS: 1US FAERS
108jaundiceFAERS: 1US FAERS
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.